UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2007
THE COOPER COMPANIES, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 1-8597 | 94-2657368 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
6140 Stoneridge Mall Road, Suite 590, Pleasanton, California 94588
(Address of principal executive offices)
(925) 460-3600
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| ITEM 7.01. | Regulation FD Disclosure. |
On November 14, 2007, The Cooper Companies, Inc. plans to make a Company presentation at a health care conference that includes additional non-public information. The presentation includes revenue guidance for fiscal 2008 at page 18. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report and shall not be deemed “filed” under the Securities Exchange Act of 1934, as amended.
Internet addresses in the release are for information purposes only and are not intended to be hyperlinks to other The Cooper Companies, Inc. information.
| ITEM 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Company presentation dated November 14, 2007 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| THE COOPER COMPANIES, INC. | ||
| By | /s/ Carol R. Kaufman | |
| Carol R. Kaufman Senior Vice President of Legal Affairs, Secretary and Chief Administrative Officer | ||
Dated: November 14, 2007
EXHIBIT INDEX
| Exhibit No. | Description |
Sequentially Numbered Page | ||
| 99.1 | Company presentation dated November 14, 2007 |
 NYSE: COO
Exhibit 99.1 |
 11/13/2007 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking projections of Cooper’s results. Actual results could differ materially from these projections. Additional information concerning factors that could cause material differences can be found in Cooper’s periodic filings with the Securities and Exchange Commission. They are available publicly and on request from Cooper’s investor relations department. |
 11/13/2007 3 THE COMPANY Medical devices Vision care Women’s healthcare Market leadership Favorable demographics Consistent long-term performance |
 11/13/2007 4 CONSISTENT PERFORMANCE (CAGR Ex Call Outs) 17% 26% 30% 2001- 2006 5 Year CGR EPS - Continuing Operations Operating Income Revenue |
 11/13/2007 5 COO BUSINESS GOALS Low to mid-teens revenue growth for next five years CVI double digit CSI high-teens, including M&A Earnings growth mid-teens to high- teens |
 11/13/2007 6 COO BUSINESS GOALS CooperVision Grow 1.5 times worldwide market next 5 years Largest specialty lens company Move to #2 position worldwide Operating margin mid to upper 20’s |
 11/13/2007 7 COO BUSINESS GOALS CooperSurgical Revenue of $300M by 2011 including acquisitions Operating margin in mid 20’s |
 11/13/2007 8 CooperVision 11/13/2007 8 |
 11/13/2007 9 MARKET SEGMENTS (worldwide, millions of $’s) 4% 8% $2,555 $1,718 $2,082 $1,191 All Other Spheres Specialty 7% $6,778 $4,732 Total Market Daily Disposable Spheres 11% $2,505 $1,459 CGR 2011 2006 |
 11/13/2007 10 GEOGRAPHIC MARKET SEGMENTS 7% $6,778 $4,732 Total Market *Includes Mideast and Africa Source: company reported data and independent market audit Asia/Pacific Europe* Americas (millions of $’s) 12% $2,555 $1,440 3% $1,559 $1,328 6% $2,665 $1,964 CGR 2011 2006 |
 11/13/2007 11 WORLD MARKET DRIVERS Growing indication: myopia Favorable demographics: teens Specialty and value-added vs. commodity: improved lens technology Geographic expansion |
 11/13/2007 12 COOPERVISION TODAY $800M in 2007 vs. $38M in 1994 #2 in Europe; #2 in US; #3 worldwide Specialty lenses Worldwide toric lens market leader |
 11/13/2007 13 Contact Lens Global Market* % change and % share *Independent audit data +5 100 +5 100 +6 100 +5 100 Total +5 43 +6 25 +6 42 +6 25 Specialty -2 43 n/c 43 -2 42 n/c 42 Reusable Sphere +29 14 +12 32 +31 16 +10 33 Single Use CVI YTD07 CVI Q307 |
 11/13/2007 14 Contact Lens Global Market* US versus ROW *Independent audit data 100% +5 100% +5 Total 22% (+1) +8 33% (n/c) +3 Specialty 33% (-3) -2 57% (-2) +2 Reusable Sphere 45% (+2) +10 10% (+2) +2 Single Use %ROW YTD07 %US YTD07 |
 11/13/2007 15 Contact Lens Global Market* % change *Independent audit data +5 +5 +6 +5 Total +21 +10 +21 +10 Asia +4 n/c +4 +1 Europe +2 +5 +6 +4 United States CVI YTD07 CVI Q307 |
 11/13/2007 16 Contact Lens Global Market* Q307 versus Q207 *Independent audit data +5 +n/c Total +5 +4 Asia n/c n/c Europe +7 -2 United States CVI MKT |
 11/13/2007 17 Contact Lens Global Market* Competitive Landscape % change *Independent audit data +5 +5 Total (100%) -5 -11 Others (40%) +5 +6 COO (17%) +15 +14 JNJ (43%) YTD Q3 |
 11/13/2007 18 Revenue Guidance ($Millions) *as issued on 9/6/07 $1,020 - $1,090 $940 - $967 TOTAL $165 - $170 $150 - $157 CSI $855 - $920 $790 - $810 CVI 2008 2007* |
 11/13/2007 19 UPDATES • Manufacturing capacity • New Products – 2 week silicone hydrogel – Silicone hydrogel toric – Proclear daily disposable in Japan |
 11/13/2007 20 Keeping you at the forefront of women’s healthcare™ WOMEN’S HEALTHCARE |
 11/13/2007 21 WOMEN’S HEALTHCARE Favorable demographics Pharma, capital equipment, in-office Fragmented market Changing market dynamics |
 11/13/2007 22 Consolidate market New in-office product opportunities Fertility and hospital procedures Disposable/reusable components COOPERSURGICAL STRATEGY |
 11/13/2007 23 PROCEDURES Cervical disease Incontinence Infertility Osteoporosis (diagnostic) Menstrual disorders Menopause Birth control |
 11/13/2007 24 COOPERSURGICAL TODAY $125M FY 2006 Consumables 85%; capital
equipment 15% In-office market segment leader Recent acquisitions U.S. 85% |
 11/13/2007 25 CSI OBJECTIVES $125M 2006 – $300M 2011 25% operating margin Expand in hospital segment 20% ROI M&A hurdle Accelerate organic growth Expand geographically |
 11/13/2007 26 NYSE:COO Financial Highlights |
 11/13/2007 27 Total Debt $861 Stockholders’ Equity $1435 Total Capitalization $2297 Total Debt /Capitalization 38% CAPITAL STRUCTURE 7-31-07 ($’s in Millions) |
 11/13/2007 28 COO CONSOLIDATED REVENUE $244 $330 $389 $698 $734 $71 $82 $101 $109 $125 $0 $100 $200 $300 $400 $500 $600 $700 $800 $900 2002 2003 2004 2005 2006 ($ in millions) $315 $412 CVI CSI $490 $807 $859 |
 11/13/2007 29 CONSOLIDATED OPERATING INCOME $189 $95 $67 $117 $175 $0 $50 $100 $150 $200 2002 2003 2004 2005 2006 0% 5% 10% 15% 20% 25% ($ in millions) Operating Income Operating Margin (Ex Call Outs) |
 11/13/2007 30 CVI CONSOLIDATED OPERATING INCOME $60 $89 $107 $171 $186 $0 $50 $100 $150 $200 2002 2003 2004 2005 2006 0% 10% 20% 30% ($ in millions) Operating Income Operating Margin (Ex Call Outs) |
 11/13/2007 31 CSI CONSOLIDATED OPERATING INCOME $20 $21 $18 $14 $24 $0 $5 $10 $15 $20 $25 2002 2003 2004 2005 2006 0% 5% 10% 15% 20% 25% ($ in millions) Operating Income Operating Margin (Ex Call Outs) |
 11/13/2007 32 TAXES Net Operating Loss Carryforwards $143 million Global Tax Arrangement Effective Tax Rates |
 11/13/2007 33 CASH FLOW FROM OPERATING ACTIVITIES $56 $80 $101 $184 $151 $0 $50 $100 $150 $200 2002 2003 2004 2005 2006 ($ in millions) |
 11/13/2007 34 HISTORY OF SUCCESSFUL DELEVERAGING 8% 38% 27% 20% 21% 34% 31% 23% 36% 35% 0% 10% 20% 30% 40% Jan.’05 – Acquired Ocular Sciences Feb.’02 – Acquired Biocompatibles Dec.’97 – Acquired Aspect Vision Nov.’06 – Acquired Lone Star Nov.’05 – Acquired Inlet & NeoSurg DEBT/CAP |
 NYSE: COO |